CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer

Background: The study of immune surveillance in the tumour microenvironment is leading to the development of new biomarkers and therapies. The present research focuses on the expression of CD5 and CD6 - two lymphocyte surface markers involved in the fine tuning of TCR signaling - as potential progno...

Descripción completa

Detalles Bibliográficos
Autores: Moreno Manuel, Andrea, Jantus Lewintre, Eloisa, Simões, Inês, Aranda, Fernando, Calabuig Fariñas, Silvia, Carreras Margalef, Esther, Zúñiga, Sheila, Saenger, Yvonne, Rosell, Rafael, Camps, Carlos, Lozano Soto, Francisco, Sirera, Rafael
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/173920
Acceso en línea:https://hdl.handle.net/2445/173920
Access Level:acceso abierto
Palabra clave:Càncer de pulmó
Melanoma
Marcadors bioquímics
Marcadors tumorals
Lung cancer
Biochemical markers
Tumor markers
id ES_736e226cb0d29026cd2e9606fd2430be
oai_identifier_str oai:diposit.ub.edu:2445/173920
network_acronym_str ES
network_name_str España
repository_id_str
spelling CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancerMoreno Manuel, AndreaJantus Lewintre, EloisaSimões, InêsAranda, FernandoCalabuig Fariñas, SilviaCarreras Margalef, EstherZúñiga, SheilaSaenger, YvonneRosell, RafaelCamps, CarlosLozano Soto, FranciscoSirera, RafaelCàncer de pulmóMelanomaMarcadors bioquímicsMarcadors tumoralsLung cancerMelanomaBiochemical markersTumor markersBackground: The study of immune surveillance in the tumour microenvironment is leading to the development of new biomarkers and therapies. The present research focuses on the expression of CD5 and CD6 - two lymphocyte surface markers involved in the fine tuning of TCR signaling - as potential prognostic biomarkers in resectable stages of non-small cell lung cancer (NSCLC). Methods: CD5 and CD6 gene expression was analysed by reverse transcription quantitative polymerase chain reaction (RTqPCR) in 186 paired fresh frozen tumour and normal tissue samples of resected NSCLC. Results: Patients with higher CD5 expression had significantly increased overall survival (OS, 49.63 vs. 99.90 months, p=0.013). CD5 expression levels were correlated to CD4 infiltration and expression levels, and survival analysis showed that patients with a higher CD5/CD4+ ratio had significantly improved prognosis. Multivariate analysis established CD5 expression as an independent prognostic biomarker for OS in early stages of NSCLC [HR=0.554; 95% CI, 0.360-0.853; p=0.007]. Further survival analysis of NSCLC cases (n=97) from The Cancer Genome Atlas (TCGA) database, confirmed the prognostic value of both CD5 and CD6 expression¸ although CD6 expression alone did not reach significant prognostic value in our NSCLC training cohort. Conclusions: Our data support further studies on CD5 and CD6 as novel prognostic markers in resectable NSCLC and other cancer types (i.e., melanoma), as well as a role for these receptors in immune surveillance.AME Publishing Company2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/173920Articles publicats en revistes (Biomedicina)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.21037/tlcr-19-445Translational Lung Cancer Research, 2020, vol. 9, num. 4, p. 1074-1083.https://doi.org/10.21037/tlcr-19-445cc-by-nc-nd (c) AME Publishing Company, 2020http://creativecommons.org/licenses/by-nc-nd/3.0/esinfo:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1739202026-05-27T06:46:51Z
dc.title.none.fl_str_mv CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer
title CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer
spellingShingle CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer
Moreno Manuel, Andrea
Càncer de pulmó
Melanoma
Marcadors bioquímics
Marcadors tumorals
Lung cancer
Melanoma
Biochemical markers
Tumor markers
title_short CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer
title_full CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer
title_fullStr CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer
title_full_unstemmed CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer
title_sort CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer
dc.creator.none.fl_str_mv Moreno Manuel, Andrea
Jantus Lewintre, Eloisa
Simões, Inês
Aranda, Fernando
Calabuig Fariñas, Silvia
Carreras Margalef, Esther
Zúñiga, Sheila
Saenger, Yvonne
Rosell, Rafael
Camps, Carlos
Lozano Soto, Francisco
Sirera, Rafael
author Moreno Manuel, Andrea
author_facet Moreno Manuel, Andrea
Jantus Lewintre, Eloisa
Simões, Inês
Aranda, Fernando
Calabuig Fariñas, Silvia
Carreras Margalef, Esther
Zúñiga, Sheila
Saenger, Yvonne
Rosell, Rafael
Camps, Carlos
Lozano Soto, Francisco
Sirera, Rafael
author_role author
author2 Jantus Lewintre, Eloisa
Simões, Inês
Aranda, Fernando
Calabuig Fariñas, Silvia
Carreras Margalef, Esther
Zúñiga, Sheila
Saenger, Yvonne
Rosell, Rafael
Camps, Carlos
Lozano Soto, Francisco
Sirera, Rafael
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Càncer de pulmó
Melanoma
Marcadors bioquímics
Marcadors tumorals
Lung cancer
Melanoma
Biochemical markers
Tumor markers
topic Càncer de pulmó
Melanoma
Marcadors bioquímics
Marcadors tumorals
Lung cancer
Melanoma
Biochemical markers
Tumor markers
description Background: The study of immune surveillance in the tumour microenvironment is leading to the development of new biomarkers and therapies. The present research focuses on the expression of CD5 and CD6 - two lymphocyte surface markers involved in the fine tuning of TCR signaling - as potential prognostic biomarkers in resectable stages of non-small cell lung cancer (NSCLC). Methods: CD5 and CD6 gene expression was analysed by reverse transcription quantitative polymerase chain reaction (RTqPCR) in 186 paired fresh frozen tumour and normal tissue samples of resected NSCLC. Results: Patients with higher CD5 expression had significantly increased overall survival (OS, 49.63 vs. 99.90 months, p=0.013). CD5 expression levels were correlated to CD4 infiltration and expression levels, and survival analysis showed that patients with a higher CD5/CD4+ ratio had significantly improved prognosis. Multivariate analysis established CD5 expression as an independent prognostic biomarker for OS in early stages of NSCLC [HR=0.554; 95% CI, 0.360-0.853; p=0.007]. Further survival analysis of NSCLC cases (n=97) from The Cancer Genome Atlas (TCGA) database, confirmed the prognostic value of both CD5 and CD6 expression¸ although CD6 expression alone did not reach significant prognostic value in our NSCLC training cohort. Conclusions: Our data support further studies on CD5 and CD6 as novel prognostic markers in resectable NSCLC and other cancer types (i.e., melanoma), as well as a role for these receptors in immune surveillance.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/173920
url https://hdl.handle.net/2445/173920
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.21037/tlcr-19-445
Translational Lung Cancer Research, 2020, vol. 9, num. 4, p. 1074-1083.
https://doi.org/10.21037/tlcr-19-445
dc.rights.none.fl_str_mv cc-by-nc-nd (c) AME Publishing Company, 2020
http://creativecommons.org/licenses/by-nc-nd/3.0/es
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by-nc-nd (c) AME Publishing Company, 2020
http://creativecommons.org/licenses/by-nc-nd/3.0/es
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv AME Publishing Company
publisher.none.fl_str_mv AME Publishing Company
dc.source.none.fl_str_mv Articles publicats en revistes (Biomedicina)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410809526878208
score 15,301603

Similares en LA Referencia